Cushing's Syndrome in Adenocarcinoma of Lung Responding to Osilodrostat

Caio Teixeira Heleno; Seung Pyo D Hong; Hyung-Gyo Cho; Min Jeong Kim; Yeonggyeong Park; Young Kwang Chae

doi:10.1159/000527824

Cushing's Syndrome in Adenocarcinoma of Lung Responding to Osilodrostat

Case Rep Oncol. 2023 Mar 1;16(1):124-128. doi: 10.1159/000527824. eCollection 2023 Jan-Dec.

Authors

Caio Teixeira Heleno¹, Seung Pyo D Hong², Hyung-Gyo Cho², Min Jeong Kim², Yeonggyeong Park², Young Kwang Chae²

Affiliations

¹ MercyOne North Iowa Medical Center, Mason City, IA, USA.
² Northwestern University, Feinberg School of Medicine, Chicago, IL, USA.

Abstract

Cushing's syndrome (CS), secondary to paraneoplastic syndrome, is more commonly seen in small cell lung cancer but never before reported in epidermal growth factor receptor-mutated adenocarcinoma of the lung. Here, we present a case of a patient whose symptoms of hypokalemia, hypertension, and progressive abnormal glucose levels led to further workup that revealed adrenocorticotropic hormone-dependent hypercortisolism. Her cortisol levels dropped after 1 month of osilodrostat treatment, while lung cancer was treated with osimertinib. The use of osilodrostat in paraneoplastic CS has been previously reported in only 3 patients.

Keywords: Case report; Ectopic adrenocorticotropic hormone-dependent Cushing; Epidermal growth factor receptor; Osilodrostat.

Publication types

Case Reports

Grants and funding

This research received no external funding from funding agencies in the public, commercial, or not-for-profit sectors.